Celltech Group (NYSE: CLL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Nealon who started this subject	4/25/2003 9:07:18 AM
From: nigel bates	Read Replies (1) of 123

Celltech falls as Merck drops its asthma drug LONDON, April 25 (Reuters) - Shares in Celltech Group Plc (London:CCH.L - News) fell nearly five percent on Friday after U.S. partner Merck & Co Inc (NYSE:MRK - News) said it would cease development of an asthma drug licensed from the British group. The stock was down 4.7 percent at 285-1/4 pence by 1255 GMT after an earlier high of 313-1/2. Past development of drugs in the same class -- known as Phosphodiesterase-4 inhibitors -- have been hindered by side effects such as vomiting. However, Merck said it would continue its research in the field of asthma and pulmonary disease through the study of other molecules in the same class...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next